KRYS

Krystal Biotech, Inc. (KRYS) | Rumor.io

Krystal Biotech

KRYS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,164

Bullish sentiment (50-day avg)97%

Price to earnings ratio42.5

Market capitalization10B

Earnings per share7.99

Dividend yield (TTM)—

Revenue (annual)389.1M

Net income (annual)204.8M

Social

What share of all stock conversation is about KRYS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Aug 3

Krystal Biotech's stock fell 9.1% pre-market due to a revenue miss despite beating earnings expectations, with sales coming in at $119.22M, missing the estimate of $121.061M.
The company reported a 24.14% YoY increase in revenue and a 39.10% YoY increase in GAAP EPS, with earnings coming in at $1.85 per share, beating the consensus estimate of $1.70.
Krystal Biotech is expanding its presence in new markets, including the UK, Spain, Italy, Switzerland, and Australia, and is expecting sequential double-digit growth in Germany.

Generated by AI

Sentiment

Of the messages about KRYS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +2.78	98.69% +11.22
Bearish	—	—	0% -2.78	1.31% -11.22

Bullish· Feb 26

$KRYS has demonstrated strong sales growth, with a 390% quarter-over-quarter increase in Vyjuvek sales to $42 million in 4Q.
The company's lead product, Vyjuvek, is expected to reach $275 million in sales, driven by its successful launch and strong market demand.
$KRYS has a clear road to a stronger-than-expected launch, with analysts revising their estimates and price targets upwards, citing the company's solid earnings and peak sales potential of $1.2B.

Bearish· Dec 1

Krystal Biotech, Inc. (KRYS) has been a disappointing investment, with the stock price moving opposite to expectations.
The company's stock has experienced significant declines, with some traders even referring to it as a "joke" or a "bear game".
Investors are advising caution, with some warning that the stock's price may drop further, citing concerns about its potential to break key support levels.

Generated by AI

Topics

Of the messages about KRYS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	50%	97.37%	15.54%
Analysts	—	50%	2.63%	0.9%
Technical Analysis	—	0%	0%	2.35%
Earnings	—	0%	0%	0.32%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	80.9%

Analysts· Nov 29

Analysts are confident about Krystal Biotech, with a buy consensus of 84% among 14 analysts.
HC Wainwright & Co. has raised its price target for Krystal Biotech to $124, with analyst Joseph Pantginis maintaining a Buy rating.
Krystal Biotech shares have more than doubled after the company announced positive topline results from its GEM-3 pivotal trial of VYJUVEK in patients with dystrophic epidermolysis bullosa.

Announcements· Aug 4

Krystal Biotech's Q2 2025 earnings beat estimates, with revenue of $96M, EPS of $1.29, and a 37.23% YoY increase in EPS.
The company's VYJUVEK therapy has been approved in the EU and Japan, and 575+ patients have been approved in the US.
Krystal Biotech's cash position stands at $820.8M, with a strong Q2 performance driven by revenue growth and a significant increase in EPS.

Generated by AI

Community

Of the messages about KRYS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	56.45%	33.4%	22.55%
Newcomers	—	43.55%	66.6%	77.45%

Regulars· Aug 4

Krystal Biotech's Q2 2025 earnings and revenue beat expectations, with adjusted EPS of $1.29 (vs. $1.17 est) and sales of $96.04M (vs. $94.25M est), representing a 37.23% YoY increase.
The company's net product revenue for Q2 2025 was $96.0M, up from $70.3M in Q2 2024, with a net income of $38.3M.
Despite a Q3 outlook that is considered weak due to EU and Japan expansion, the pipeline is progressing, with cystic fibrosis data expected at year-end, and the company remains profitable.

Newcomers· Aug 4

The company's Q2 earnings beat estimates with revenue of $96M and EPS of $1.29, driven by strong sales of its VYJUVEK therapy.
New patient approvals in the US and EU/Japan approval for VYJUVEK therapy are expected to be transformative for the company's growth.
Despite the strong earnings, the stock price dropped due to market concerns over a potential DOJ investigation and client concentration risks, but many analysts still see long-term potential for the company.

Generated by AI

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.16% on an annualized basis producing an average annual return of 44.36%. Currently, Krystal Biotech has a market capitalization of

4d agoBenzinga

Krystal Biotech stock initiated at buy by Goldman Sachs

6d agoInvesting.com

BofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy Rating

Krystal Biotech (KRYS) has an average rating of buy and mean price target of $386, according to anal

8d agoYahoo Finance

Krystal Biotech at Cantor healthcare conference: pipeline gains pace

19d agoInvesting.com

Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years

19d agoBenzinga

Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing

Krish S Krishnan, 10% Owner, Director, President and Chief Executive Officer, on September 04, 2026,

22d agoYahoo Finance

Also Discussed

Investors talking about KRYS also mention

#	Name	Attention
1	Abeona Therapeutics Inc.ABEO	0%+0
2	SWTX - SpringWorks Therapeutics, Inc.	——
3	BPMC - Blueprint Medicines Corporation	——
4	Regenxbio Inc.RGNX	0%+0
5	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
6	BridgeBio Pharma Inc.BBIO	0%-0.02
7	Bicycle Therapeutics plc - ADRBCYC	0%0
8	APLS - Apellis Pharmaceuticals, Inc.	——
9	Ultragenyx Pharmaceutical Inc.RARE	0.01%+0.01
10	Denali Therapeutics Inc.DNLI	0%new

Krystal Biotech, Inc.

Healthcare
Biotechnology

Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for serious and rare diseases. Its lead product, VYJUVEK, is a redosable gene therapy approved for dystrophic epidermolysis bullosa, a rare inherited skin disorder. The company’s work centers on its proprietary HSV-1-based delivery platform, which supports programs across dermatology, respiratory, ophthalmology, oncology, and aesthetics. Through this platform, Krystal Biotech develops therapies designed to address high unmet medical needs and expand treatment options in specialized disease areas. Headquartered in Pittsburgh, Pennsylvania, Krystal Biotech plays a notable role in the gene therapy market by combining commercial operations with a broader pipeline of investigational genetic medicine candidates.

Website

Location

2100 Wharton Street

Pittsburgh, PA, 15203

United States

Social

What share of all stock conversation is about KRYS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Aug 3

Krystal Biotech's stock fell 9.1% pre-market due to a revenue miss despite beating earnings expectations, with sales coming in at $119.22M, missing the estimate of $121.061M.
The company reported a 24.14% YoY increase in revenue and a 39.10% YoY increase in GAAP EPS, with earnings coming in at $1.85 per share, beating the consensus estimate of $1.70.
Krystal Biotech is expanding its presence in new markets, including the UK, Spain, Italy, Switzerland, and Australia, and is expecting sequential double-digit growth in Germany.

Generated by AI

Sentiment

Of the messages about KRYS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +2.78	98.69% +11.22
Bearish	—	—	0% -2.78	1.31% -11.22

Bullish· Feb 26

$KRYS has demonstrated strong sales growth, with a 390% quarter-over-quarter increase in Vyjuvek sales to $42 million in 4Q.
The company's lead product, Vyjuvek, is expected to reach $275 million in sales, driven by its successful launch and strong market demand.
$KRYS has a clear road to a stronger-than-expected launch, with analysts revising their estimates and price targets upwards, citing the company's solid earnings and peak sales potential of $1.2B.

Bearish· Dec 1

Krystal Biotech, Inc. (KRYS) has been a disappointing investment, with the stock price moving opposite to expectations.
The company's stock has experienced significant declines, with some traders even referring to it as a "joke" or a "bear game".
Investors are advising caution, with some warning that the stock's price may drop further, citing concerns about its potential to break key support levels.

Generated by AI

Topics

Of the messages about KRYS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	50%	97.37%	15.54%
Analysts	—	50%	2.63%	0.9%
Technical Analysis	—	0%	0%	2.35%
Earnings	—	0%	0%	0.32%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	80.9%

Analysts· Nov 29

Analysts are confident about Krystal Biotech, with a buy consensus of 84% among 14 analysts.
HC Wainwright & Co. has raised its price target for Krystal Biotech to $124, with analyst Joseph Pantginis maintaining a Buy rating.
Krystal Biotech shares have more than doubled after the company announced positive topline results from its GEM-3 pivotal trial of VYJUVEK in patients with dystrophic epidermolysis bullosa.

Announcements· Aug 4

Krystal Biotech's Q2 2025 earnings beat estimates, with revenue of $96M, EPS of $1.29, and a 37.23% YoY increase in EPS.
The company's VYJUVEK therapy has been approved in the EU and Japan, and 575+ patients have been approved in the US.
Krystal Biotech's cash position stands at $820.8M, with a strong Q2 performance driven by revenue growth and a significant increase in EPS.

Generated by AI

Community

Of the messages about KRYS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	56.45%	33.4%	22.55%
Newcomers	—	43.55%	66.6%	77.45%

Regulars· Aug 4

Krystal Biotech's Q2 2025 earnings and revenue beat expectations, with adjusted EPS of $1.29 (vs. $1.17 est) and sales of $96.04M (vs. $94.25M est), representing a 37.23% YoY increase.
The company's net product revenue for Q2 2025 was $96.0M, up from $70.3M in Q2 2024, with a net income of $38.3M.
Despite a Q3 outlook that is considered weak due to EU and Japan expansion, the pipeline is progressing, with cystic fibrosis data expected at year-end, and the company remains profitable.

Newcomers· Aug 4

The company's Q2 earnings beat estimates with revenue of $96M and EPS of $1.29, driven by strong sales of its VYJUVEK therapy.
New patient approvals in the US and EU/Japan approval for VYJUVEK therapy are expected to be transformative for the company's growth.
Despite the strong earnings, the stock price dropped due to market concerns over a potential DOJ investigation and client concentration risks, but many analysts still see long-term potential for the company.

Generated by AI

Krystal Biotech

Social

Aug 3

Bullish· Feb 26

Bearish· Dec 1

Analysts· Nov 29

Announcements· Aug 4

Regulars· Aug 4

Newcomers· Aug 4

Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today - Krystal Biotech (NAS

Krystal Biotech stock initiated at buy by Goldman Sachs

BofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy Rating

Krystal Biotech at Cantor healthcare conference: pipeline gains pace

Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years

Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing

Also Discussed

Krystal Biotech, Inc.

Company Information

Location

Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today - Krystal Biotech (NAS

Krystal Biotech stock initiated at buy by Goldman Sachs

BofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy Rating

Krystal Biotech at Cantor healthcare conference: pipeline gains pace

Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years

Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing

Also Discussed

Social

Aug 3

Bullish· Feb 26

Bearish· Dec 1

Analysts· Nov 29

Announcements· Aug 4

Regulars· Aug 4

Newcomers· Aug 4